RESUMO
BACKGROUND: Vaccine effectiveness (VE) estimates vary by population characteristics and circulating variants. North America and Europe have generated many COVID-19 VE estimates but relied heavily on mRNA vaccines. Fewer estimates are available for non-mRNA vaccines and from Latin America. We aimed to estimate the effectiveness of several COVID-19 vaccines in preventing SARS-CoV-2-associated severe acute respiratory infection (SARI) in Paraguay from May 2021 to April 2022. METHODS: Using sentinel surveillance data from four hospitals in Paraguay, we conducted a test-negative case-control study to estimate COVID-19 vaccine effectiveness against SARI by vaccine type/brand and period of SARS-CoV-2 variant predominance (Gamma, Delta, Omicron). We used multivariable logistic regression adjusting for month of symptom onset, age group, and presence of ≥1 comorbidity to estimate the odds of COVID-19 vaccination in SARS-CoV-2 test-positive SARI case-patients compared to SARS-CoV-2 test-negative SARI control-patients. RESULTS: Of 4,229 SARI patients, 2,381 (56%) were SARS-CoV-2-positive case-patients and 1,848 (44%) were SARS-CoV-2-negative control-patients. A greater proportion of case-patients (73%; 95% CI: 71-75) than of control-patients (40%; 95% CI: 38-42) were unvaccinated. During the Gamma variant-predominant period, VE estimates for partial vaccination with mRNA vaccines and Oxford/AstraZeneca Vaxzevria were 90.4% (95% CI: 66.4-97.6) and 52.2% (95% CI: 25.0-69.0), respectively. During the Delta variant-predominant period, VE estimates for complete vaccination with mRNA vaccines, Oxford/AstraZeneca Vaxzevria, or Gamaleya Sputnik V were 90.4% (95% CI: 74.3-97.3), 83.2% (95% CI: 67.8-91.9), and 82.9% (95% CI: 53.0-95.2), respectively. The effectiveness of all vaccines declined substantially during the Omicron variant-predominant period. CONCLUSIONS: This study contributes to our understanding of COVID-19 VE in Latin America and to global understanding of vaccines that have not been widely used in North America and Europe. VE estimates from Paraguay can parameterize models to estimate the impact of the national COVID-19 vaccination campaign in Paraguay and similar settings.
RESUMO
RESUMEN Introducción: La pandemia de COVID-19 produjo una crisis sanitaria afectando las coberturas de vacunación de los países. Objetivo : Describir la cobertura de vacunación de los biológicos trazadores durante el periodo prepandémico (2015- 2019) y pandémico (2020-2021) en Paraguay. Materiales y Métodos: Estudio descriptivo observacional de corte transverso, que comprendió a niños de 0 a 5 años de edad, de las 18 Regiones Sanitarias del País. Se analizaron las coberturas de vacunación del Programa Ampliado de Inmunización, periodo prepandémico (2015-2019) y pandémico (2020-201). Se incluyeron los biológicos trazadores: BCG, DPT1, DPT3, IPV1 y bOPV3, SPR1, SPR2 y vacuna antiamarílica (AA), el cálculo de cobertura de vacunación a nivel país se realizó por medio del análisis del reporte electrónico semanal de dosis de vacunas administradas por Región Sanitaria. Se estableció la comparación de las coberturas de vacunación por biológico trazador, por periodos y rango de edad. Resultados: Durante la pandemia se constató un descenso de cobertura de vacunación de los biológicos trazadores, para BCG: 4 % (2020), 15% (2021);DPT1: 5 % (2020), 13 % (2021); DPT3: 9 % (2020), 22 %(2021); IPV1: 5 % (2020),16 % (2021); bOPV3: 7% (2020),19 % (2021); SPR1: 9 %, SPR2: 13 % (2020),SPR1:17%, SPR2:16 % (2021) y AA: 7% (2020), 15% (2021). Conclusión: Durante la pandemia de Covid-19 disminuyeron las coberturas de vacunación de todos los biológicos trazadores, similar descenso se constató en otros países de América, existe el riesgo de aparición de brotes de enfermedades prevenibles por vacunación por el acúmulo de susceptibles.
ABSTRACT Introduction: The COVID-19 pandemic produced a health crisis affecting countries' vaccination coverage statistics. Objective: To describe the coverage of recommended vaccines during the pre-pandemic (2015-2019) and pandemic (2020-2021) periods in Paraguay. Materials and Methods: This was a descriptive, observational cross-sectional study, comprising children from 0 to 5 years of age, from the Country's 18 Health Regions. The vaccination coverage of the National Expanded Immunization Program, pre-pandemic (2015-2019) and pandemic (2020-201) periods were analyzed. The recommended vaccinations included were: BCG, DTP1, DTP3, IPV1 and bOPV3, MMR1, MMR2 and yellow fever vaccine (AA), the calculation of vaccination coverage at the country level was carried out through the analysis of the weekly electronic report of doses of vaccines administered by Health Region. The comparison of vaccination coverage by recommended vaccine was established, by periods and age range. Results: During the pandemic, a decrease in vaccination coverage of the recommended vaccines was observed, for BCG: 4% (2020), 15% (2021); DTP1: 5% (2020), 13% (2021); DTP3: 9% (2020), 22% (2021); IPV1: 5% (2020), 16% (2021); bOPV3: 7% (2020), 19% (2021); MMR1: 9%, MMR2: 13% (2020), MMR1: 17%, MMR2: 16% (2021) and AA: 7% (2020), 15% (2021). Conclusion: During the Covid-19 pandemic, vaccination coverage of all recommended vaccines decreased, a similar decrease was found in other countries in the Americas, there is a risk of outbreaks of vaccine-preventable diseases due to the accumulation of susceptible populations.
RESUMO
La Púrpura Trombocitopénica Idiopática representa la forma más frecuente de trombocitopenia en la infancia, en ausencia de un trastorno sistémico asociado identificable en la mayoría de los casos. El lupus eritematoso sistémico es una enfermedad de base genética, autoinmune, crónica, multisistémica. El Lupus Eritematoso Incompleto es aquel que se presenta en pacientes que no reúnen criterios de clasificación para lupus eritematoso sistémico de acuerdo al ACR (American College of Rheumatology), junto con Anticuerpos Antinucleares positivos. Se presenta el caso de una lactante menor de 5 meses de edad con diagnóstico de Lupus Eritematoso Incompleto (la menor reportada hasta el momento) que inició su enfermedad con Púrpura Trombocitopénica Autoinmune, además de anticuerpos antinucleares y anticardiolipinas positivos sin afectación en otros sistemas. Por lo que consideramos que la prueba de anticuerpos antinucleares debe solicitarse en casos de púrpura trombocitopénica autoinmune, con el seguimiento adecuado, ya que esta prueba positiva es considerada de riesgo para el desarrollo posterior de lupus eritematoso sistémico, a fin de prevenir daños importantes y mejorar el pronóstico de la enfermedad.
Idiopathic thrombocytopenic purpura is the most common form of thrombocytopenia during childhood, and usually appears without an associated systemic condition being identified. Systemic Lupus Erythematosus is a chronic and multisystemic genetically-based autoimmune disease. Incomplete lupus erythematosus is considered to be present when the patient does not mean the criteria for systemic lupus erythematosus devised by the American College of Rheumatology (ACR) together with positive anti-nuclear antibody titer levels. We present the case of a five-month old female infant diagnosed with incomplete lupus erythematosus (as of current data) whose condition first manifested as autoimmune thrombocytopenic purpura and whose antinuclear and anticardiolipin antibodies titers were positive, but without detected effects on other systems. Since this test is considered to determine the existence of risk of later development of systemic lupus erythematosus, we suggest that antinuclear antibody testing should be requested in cases of autoimmune thrombocytopenic purpura and that adequate follow up be carried out to help avoid negative outcomes and improve patient prognosis.